{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:01:08Z","timestamp":1794916868348,"version":"4.9.1"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,1,15]]},"DOI":"10.2169\/internalmedicine.1410-22","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T22:12:20Z","timestamp":1684879940000},"page":"213-219","source":"Crossref","is-referenced-by-count":18,"title":["Early Initiation of Plasma Exchange Therapy for Anti-MDA5&lt;sup&gt;+&lt;\/sup&gt;Dermatomyositis with Refractory Rapidly Progressive Interstitial Lung Disease"],"prefix":"10.2169","volume":"63","author":[{"given":"Noriko","family":"Sasaki","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Nakagome","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Kojima","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Shimura","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokai University Hachioji Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ishii","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Izumi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Hirano","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Kurabayashi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokai University Hachioji Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Hosono","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiho","family":"Yamada","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52: 1571-1576, 2005.","DOI":"10.1002\/art.21023"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 60: 2193-2200, 2009.","DOI":"10.1002\/art.24621"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nakashima R, Imura Y, Kobayashi S, et al. The RIG-Ilike receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49: 433-440, 2010.","DOI":"10.1093\/rheumatology\/kep375"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Chen Z, Cao M, Plana MN, et al. Utility of antimelanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res 65: 1316-1324, 2013.","DOI":"10.1002\/acr.21985"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the effectiveness and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol 72: 488-498, 2020.","DOI":"10.1002\/art.41105"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hayashi M, Kikuchi T, Takada T. Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibodies. Clin Rheumatol 36: 239-240, 2017.","DOI":"10.1007\/s10067-016-3443-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford) 57: 2114-2119, 2018.","DOI":"10.1093\/rheumatology\/key188"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med 381: 291-293, 2019.","DOI":"10.1056\/NEJMc1900045"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. So H, Wong VTL, Lao VWN, Pang HT, Yip RML. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody positive amyopathic dermatomyositis. Clin Rheumatol 37: 1983-1989, 2018.","DOI":"10.1007\/s10067-018-4122-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Koguchi-Yoshioka H, Okiyama N, Iwamoto K, et al. Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules\/papules. Br J Dermatol 177: 1442-1446, 2017.","DOI":"10.1111\/bjd.15499"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Abe Y, Kusaoi M, Tada K, Yamaji K, Tamura N. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology (Oxford) 59: 767-771, 2020.","DOI":"10.1093\/rheumatology\/kez357"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sasaki N, Ishii A, Kurabayashi T, et al. Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease. Mod Rheumatol Case Rep 5: 87-94, 2021.","DOI":"10.1080\/24725625.2020.1826641"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Shirakashi M, Nakashima R, Tsuji H, et al. Effectiveness of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford) 59: 3284-3292, 2020.","DOI":"10.1093\/rheumatology\/keaa123"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Takahashi R, Yoshida T, Morimoto K, et al. Successful treatment of anti-MDA5 antibody-positive dermatomyositis-associated rapidly progressive-interstitial lung disease by plasma exchange: two case reports. Clin Med Insights Case Rep 14: 11795476211036322, 2021.","DOI":"10.1177\/11795476211036322"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ishiwari M, Togashi Y, Takoi H, et al. Early intervention of plasma exchange combined with intensive immunosuppressive treatment for anti-MDA-5 antibody-positive rapidly progressive interstitial pneumonia: two case reports. Respir Med Case Rep 33: 101464, 2021.","DOI":"10.1016\/j.rmcr.2021.101464"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292: 344-347, 1975.","DOI":"10.1056\/NEJM197502132920706"},{"key":"17","unstructured":"17. Lundberg IE, Tjarnlund A, Bottai M, et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol 69: 2271-2282, 2017."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46: 626-636, 2002.","DOI":"10.1067\/mjd.2002.120621"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gono T, Masui K, Nishina N, et al. Risk prediction modeling based on a combination of initial serum biomarker levels in polymyositis\/dermatomyositis-associated interstitial lung disease. Arthritis Rheumatol 73: 677-686, 2021.","DOI":"10.1002\/art.41566"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kagawa H, Tsujino K, Yamamoto Y, et al. Acute lung injury after plasma exchange in a patient with anti-MDA5 antibody-positive, rapidly progressive, interstitial lung disease: a case report. Respir Med Case Rep 29: 101016, 2020.","DOI":"10.1016\/j.rmcr.2020.101016"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol 12: 773352, 2021.","DOI":"10.3389\/fimmu.2021.773352"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 23: 496-502, 2013.","DOI":"10.3109\/s10165-012-0663-4"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Matsushita T, Mizumaki K, Kano M, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol 176: 395-402, 2017.","DOI":"10.1111\/bjd.14882"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/2\/63_1410-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T03:20:22Z","timestamp":1705720822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/2\/63_1410-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1410-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"article-number":"1410-22"}}